Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.55 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100212 | 1.00 | CHRNA7 (0.55) | CHRNA7CNR1F2RCHRNB2CHRNB4 | |
| SCHEMBL6632916 | 1.00 | CHRNA7 (0.55) | CHRNA7CNR1F2RCHRNB2CHRNB4 | |
| SCHEMBL6100081 | 0.94 | CHRNA7 (0.47) | CHRNA7CNR1F2RCHRNB2CHRNB4 | |
| SCHEMBL6097101 | 0.88 | CHRNA7 (0.53) | CHRNA7F2RCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6097107 | 0.88 | CHRNA7 (0.53) | CHRNA7F2RCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6101043 | 0.85 | CHRNA7 (0.58) | CHRNA7CNR1PRKAA2 | |
| SCHEMBL6101050 | 0.85 | CHRNA7 (0.58) | CHRNA7CNR1PRKAA2 | |
| SCHEMBL6098953 | 0.85 | CHRNA7 (0.55) | CHRNA7F2RCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6098946 | 0.85 | CHRNA7 (0.55) | CHRNA7F2RCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6098653 | 0.84 | CHRNA7 (0.59) | CHRNA7CNR1PRKAA2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CHRNA7 1836/4885CNR1 343/4885F2R 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.